Cardiovascular risk markers in hemodialysis patients

S Urso1, M Garozzo, F Milone

  • 1Unità Operativa di Nefrologia e Dialisi, Ospedale S. Marta e S. Venera, Acireale CT, Italy.

Insights

Hemodialysis patients often have misdiagnosed heart attacks due to unreliable markers. This study found that cardiac troponin I and CK-MB mass levels remain stable during hemodialysis, suggesting their utility in diagnosing ischemic heart disease in these patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Chemistry

Background:

  • Cardiovascular events are a leading cause of mortality in hemodialysis patients.
  • Acute myocardial infarction diagnosis is challenging in uremic patients due to elevated cardiac biomarker false positivity.
  • Previous studies indicate predialytic troponin T and CK-MB mass correlate with adverse cardiac events.

Purpose of the Study:

  • To evaluate the impact of standard hemodialysis (HD) and on-line hemodiafiltration (HDF) on serum troponin I and CK-MB mass levels.
  • To determine if these cardiac biomarkers can be reliably used for diagnosing ischemic heart disease in hemodialysis patients.

Main Methods:

  • A prospective study comparing 16 uremic patients on standard HD with 6 patients on on-line HDF.
  • Exclusion of patients with pre-existing cardiac ischemic disease.
  • Measurement of pre- and post-dialysis serum troponin I and CK-MB mass, along with other parameters like Kt/V and URR%.

Main Results:

  • Serum troponin I and CK-MB mass did not significantly change pre- vs. post-dialysis in either HD or on-line HDF groups.
  • In standard HD, postdialytic troponin I correlated with serum sodium, potassium, and chlorine.
  • Postdialytic CK-MB mass correlated with serum chlorine in standard HD and serum potassium in on-line HDF.

Conclusions:

  • Hemodialytic treatments (standard HD and on-line HDF) do not alter serum troponin I and CK-MB mass levels.
  • These cardiac biomarkers can be utilized for the diagnostic approach to acute or chronic ischemic heart disease in hemodialysis patients.
  • The stability of these markers supports their clinical utility despite potential confounding factors in uremic patients.

Related Concept Videos

Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...